
Methodology: Every two weeks we collect most relevant posts on LinkedIn for selected topics and create an overall summary only based on these posts. If you´re interested in the single posts behind, you can find them here: https://linktr.ee/thomasallgeyer. Have a great read!
Thanks to Jeevan G., Marcelo Trevino, Joel Kent, Stephen Gilbert, Tareq Madi, Stanislas Niox-Chateau, Balázs Kégl, Asim Khan, Philip Rackliffe, Taha Kass-Hout, Mathias Goyen, Stacy Kelleher, Taleb Kobeissi, Martin Janich, Karley Yoder, Nehal Sejpal, Julius A., Jianbin Chen, Pierre Farmer, Elodie Sax, Èric Lluch, Dina Haman, Harikeshav Narayan, Marc DE MARTINI, Jiya Tomar, Jan Beger, Carlos Montefusco Pereira, Jen Doyle, Mikko Vasama and Michał Kępowicz and everyone else who contributed insights to this edition.
Find the full list of posts and voices on LinkedIn: https://www.linkedin.com/pulse/best-linkedin-cw-44-45-health-tech-thomas-allgeyer-m3ihe/
They are shifting from one-off approval to ongoing oversight. The UK government accepted all 44 recommendations of its National Commission on AI in healthcare. The FDA's discussion paper on generative AI devices raises 26 open questions and puts more weight on continuous validation and postmarket monitoring.
By how well they fit the workflow, not by benchmark scores. Radiology and pathology are moving from single algorithms to platforms that orchestrate people, data and workflows. In a Becker's and Philips survey, fragmented systems and limited interoperability were the top barriers to AI in patient monitoring.
Into surgical robotics, diagnostics platforms and AI-driven drug development. Medical Microinstruments raised a $125M Series D, NVIDIA plans a minority stake in Doctolib, and Oracle Health is partnering with AstraZeneca on AI agents for clinical trials. Siemens Healthineers also introduced Olyrian Diagnostics ahead of a standalone future.
How we solve real problems for real clients